Urine antibody against human cancer antigen NY-ESO-1 by Jäger, Dirk et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2002
Urine antibody against human cancer antigen NY-ESO-1
Jäger, Dirk; Stockert, Elisabeth; Karbach, Julia; Herrlinger, Kristina; Atmaca, Akin; Arand, Michael;
Chen, Yao-Tseng; Gnjatic, Sacha; Old, Lloyd J; Knuth, Alexander; Jäger, Elke
Abstract: NY-ESO-1 is one of the most immunogenic tumor antigens known to date. Spontaneous
humoral and cellular immune responses against NY-ESO-1 are detected in a substantial proportion of
patients with NY-ESO-1 positive cancers. NY-ESO-1 serum antibody is dependent on the presence of
NY-ESO-1+ cancer cells, and antibody titers correlate with the clinical development of the disease. NY-
ESO-1 serum antibody is associated with detectable NY-ESO-1-specific CD8+ T cell reactivity. High
titers of NY-ESO-1 serum antibodies are found in patients with advanced NY-ESO-1+ malignancies.
Urine samples of seropositive patients with normal kidney function were tested for NY-ESO-1 antibody
by Western blotting and enzyme-linked immunosorbent assay (ELISA). Antibodies to NY-ESO-1 were
found in the urine of patients whose NY-ESO-1 serum antibody titers were 1:10,000 or higher by Western
blotting. In patients with weak (positive at 1:250, negative at 1:1,000) or no reactivity, urine antibody was
not detectable. No urine NY-ESO-1 antibody was found in patients without detectable NY-ESO-1 serum
antibody. Our results show that urine analysis for NY-ESO-1 antibody identifies patients with strong
NY-ESO-1 immunity. Urine antibody detection may also be of value in the monitoring of spontaneous
and vaccine-induced immunity against other defined tumor antigens.
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-113616
Published Version
Originally published at:
Jäger, Dirk; Stockert, Elisabeth; Karbach, Julia; Herrlinger, Kristina; Atmaca, Akin; Arand, Michael;
Chen, Yao-Tseng; Gnjatic, Sacha; Old, Lloyd J; Knuth, Alexander; Jäger, Elke (2002). Urine antibody
against human cancer antigen NY-ESO-1. Cancer Immunity, 2:10.
Cancer Immunity 2:10 (2002) - ARTICLE
LATEST PAPERS SEARCH for PAPERS Printer-friendly PDF Comment(s)
>Abstract >Introduction >Results >Discussion >References >Materials & methods >Contact authors
Cancer Immunity, Vol. 2, p. 10 (6 August 2002) Submitted: 17 June 2002. Accepted: 24 July 2002. 
Contributed by: A Knuth 
Urine antibody against human cancer antigen NY-ESO-1
Dirk Jäger1, Elisabeth Stockert2, Julia Karbach1, Kristina Herrlinger1, Akin Atmaca1, Michael Arand3, Yao-
Tseng Chen2, Sacha Gnjatic2, Lloyd J. Old2, Alexander Knuth1, and Elke Jäger1
1II. Medizinische Klinik, Hämatologie - Onkologie, Krankenhaus Nordwest, Frankfurt, Germany
2Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan-Kettering Cancer Center, New York, USA
3Institut für Toxikologie, Johannes Gutenberg Universität, Mainz, Germany 
Keywords: human, tumor antibodies, urine, NY-ESO-1, Western blotting, ELISA
 
 
Abstract
NY-ESO-1 is one of the most immunogenic tumor antigens known to date. Spontaneous humoral and cellular 
immune responses against NY-ESO-1 are detected in a substantial proportion of patients with NY-ESO-1 
positive cancers. NY-ESO-1 serum antibody is dependent on the presence of NY-ESO-1+ cancer cells, and 
antibody titers correlate with the clinical development of the disease. NY-ESO-1 serum antibody is associated 
with detectable NY-ESO-1-specific CD8+ T cell reactivity. High titers of NY-ESO-1 serum antibodies are found in 
patients with advanced NY-ESO-1+ malignancies. Urine samples of seropositive patients with normal kidney 
function were tested for NY-ESO-1 antibody by Western blotting and enzyme-linked immunosorbent assay 
(ELISA). Antibodies to NY-ESO-1 were found in the urine of patients whose NY-ESO-1 serum antibody titers 
were 1:10,000 or higher by Western blotting. In patients with weak (positive at 1:250, negative at 1:1,000) or no 
reactivity, urine antibody was not detectable. No urine NY-ESO-1 antibody was found in patients without 
detectable NY-ESO-1 serum antibody. Our results show that urine analysis for NY-ESO-1 antibody identifies 
patients with strong NY-ESO-1 immunity. Urine antibody detection may also be of value in the monitoring of 
spontaneous and vaccine-induced immunity against other defined tumor antigens. 
 
Introduction
Major progress has been made in the analysis of immune responses against cancer through the molecular 
characterization of human cancer antigens. Based on the specific recognition by humoral or cellular effectors of 
the immune system, a large number of tumor-associated antigens has been identified (1, 2, 3). They can be 
categorized according to their expression patterns, function or origin into 6 groups: (i) Cancer-Testis (CT) 
antigens, i.e. MAGE, NY-ESO-1, LAGE1, SSX, which are expressed in a range of different tumor types and 
normal germ cells (4, 5, 6, 7, 8); (ii) differentiation antigens, i.e. Melan A/MART-1, tyrosinase, gp100, NY-BR-1, 
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which are expressed in cancer cells and the corresponding normal tissue (9, 10, 11, 12, 13); (iii) mutated normal 
genes, i.e. p53, MUM-1, CDK-4 (14, 15, 16); (iv) overexpressed `self´ antigens, i.e. HER2/neu, p53 (16, 17); (v) 
viral antigens, i.e. EBV, HPV (18, 19) and (vi) splice variants of normal genes, i.e. ING1, NY-CO-37, NY-CO-38 
(20, 21). Most of these antigens were initially defined by either cellular or humoral immune responses. Some of 
these were later shown to elicit integrated immune responses involving both humoral and cellular effectors (22, 
23, 24).
The CT antigen NY-ESO-1, initially identified by serological expression cloning of a recombinant cDNA library 
obtained from a squamous cell carcinoma of the esophagus, elicits both humoral and cellular immune responses 
in patients with NY-ESO-1+ cancers (8, 23, 25, 26). The presence of NY-ESO-1 serum antibody was found to be 
predictive of CD8+ T cell responses against NY-ESO-1-derived peptide epitopes presented by different MHC 
class I alleles (23, 27). CD4+ T cell responses to MHC class II-presented peptides were also found in patients 
with serum antibody to NY-ESO-1 (28, 29). Spontaneous changes in NY-ESO-1 antibody titers analyzed over 
extended periods of time were directly correlated with the clinical development of NY-ESO-1+ disease (25). 
Because specific IgG antibody in urine has been reported in various infectious diseases (30, 31, 32, 33), we 
investigated whether NY-ESO-1 antibody could be detected in urine. Our results have implications for the 
development of urine-based tests for the monitoring of antibody responses against NY-ESO-1 and other cancer 
antigens. 
 
Results
NY-ESO-1 serum antibody
Western blot assays and ELISAs have previously been standardized to detect NY-ESO-1 serum antibody. Both 
methods yield consistent results for large series of serum samples (25, 26). In this study, NY-ESO-1 serum 
antibody reactivity was assessed primarily by Western blot analysis. Of 47 patients tested, 21 had a strong NY-
ESO-1 serum antibody reactivity detectable at a serum dilution of 1:10,000 (Table 1). Seven patients had weak 
serum antibody reactivity (faint bands at serum dilutions of 1:250, negative at 1:1,000), and 19 patients had no 
detectable NY-ESO-1 serum antibody. ELISA and Western blotting was performed in parallel on a group of sera. 
Sera with strong reactivity in Western blotting were positive in ELISA, while sera with weak reactivity in Western 
blotting were negative in ELISA (data not shown).
NY-ESO-1 urine antibody 
Urine samples of all 47 patients were tested for NY-ESO-1 antibody by Western blot. The results presented in 
Table 1 show that strong NY-ESO-1 serum antibody reactivity (at a dilution of 1:10,000) was associated with 
detectable NY-ESO-1 urine antibody in all 21 patients at urine dilutions of 1:1 and 1:100. Western blot analysis of 
serum and urine samples for patients with strong, weak and no serum reactivity is shown in Figure 1. No NY-
ESO-1 urine antibody was found when serum reactivity was weak or negative. Since changes in NY-ESO-1 
serum antibody titers over time were observed for some patients, the serum and urine samples analyzed in this 
study were collected on the same day or within 4 weeks. ELISA results were uninterpretable for most urine 
samples due to high background reactivity, though a low specific reaction with urine was seen for a few patients 
with antibody-positive serum. Patients with weak or negative serum reactivity in Western blots had negative 
ELISA results for both serum and urine samples.
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Table 1. NY-ESO-1 serum and urine antibody status in patients with advanced NY-ESO-1+ cancersa.
 
aSera were analyzed for the presence of NY-ESO-1 antibody by Western blotting at dilutions ranging from 1:250 to 1:10,000. Antibody 
reactivity was considered strong (++) when detectable at a serum dilution of 1:10,000, weak (+) when detectable at a serum dilution 
1:250, and negative (-) when no reactivity was detected. Urine samples were assessed at dilutions ranging from 1:1 to 1:1,000 for the 
presence of NY-ESO-1 antibody. Antibody reactivity was considered positive (+) when detectable at a urine dilution of 1:100 and 
negative (-) when no reactivity was detected in the undiluted sample. Abbreviations: NSCLC, non-small cell lung cancer; NEC, neuro-
endocrine carcinoma; NHL, non-Hodgkin's lymphoma; SCLC, small cell lung cancer; CAC, cholangiocellular carcinoma.
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Figure 1. Western blot analysis of serum and urine samples. These are shown for a patient 
with strong (NW29), weak (NW1241), and negative (NW886) NY-ESO-1 serum antibody 
reactivity. Blots with 1 µg/lane recombinant NY-ESO-1 `short´ protein (14 kDa) were probed with 
serum (s; 1:1,000 dilution), urine (u; 1:100 dilution) and the E978 mouse monoclonal antibody as 
positive control (1:250 dilution). As negative controls, no serum (0) and serum obtained from a 
healthy donor (HD) were used at a 1:250 dilution.
To exclude non-specific reactivity with the recombinant NY-ESO-1 protein, sera and urine samples were also 
tested against naturally produced NY-ESO-1 protein in cell lysates. Figure 2 shows a Western blot using lysates 
of COS-7 cells transfected with NY-ESO-1 and different urine dilutions. A Western blot using lysates of the NY-
ESO-1-expressing melanoma cell line NW-MEL-38 and serum and urine samples from the same patient is 
shown in Figure 3.
Figure 2. Western blot analysis of urine from a patient with NY-ESO-1+ thyroid cancer 
(NW1231). The urine, diluted 1:1, 1:100, and 1:1,000, was used to probe a blot with the lysate of 
5x106 COS-7 cells transfected with NY-ESO-1 and thus containing naturally produced NY-ESO-1 
protein (22 kDa). NY-ESO-1 urine antibody was detected at urine dilutions of 1:1 and 1:100. Urine 
from a healthy donor (HD) at a dilution of 1:1 served as a negative control. All samples tested 
show non-specific reactivity with a COS-7 cell component (16 kDa).
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Figure 3. Western blot analysis of samples from melanoma patient NW29. A lysate of 5x106 
NW-MEL-38 melanoma cells, which naturally express NY-ESO-1 (22 kDa), was used for the 
Western blot. Serum (s; dilution 1:250) and urine (u; dilution 1:1) samples from melanoma patient 
NW29 were tested for the presence of NY-ESO-1 antibody. Serum from a healthy donor (HD) at a 
dilution of 1:250 served as a negative control.
Discussion
Humoral and cellular immune responses against human tumor antigens have been observed in patients with 
different types of cancer (34). The CT antigen NY-ESO-1 is one of the most immunogenic tumor antigens, 
eliciting spontaneous immune responses in a substantial proportion of patients with NY-ESO-1+ cancers. NY-
ESO-1 serum antibody is a reliable indicator for NY-ESO-1-specific CD8+ T cell responses, and antibody titers 
correlate with the clinical course of NY-ESO-1+ malignancies. Therefore, the assessment of NY-ESO-1 serum 
antibody has become an important tool to monitor spontaneous and vaccine-induced immunity to NY-ESO-1.
NY-ESO-1 urine antibody was detected in cancer patients who had strong serum reactivity. Because of the high 
non-specific background reactivity often observed in ELISA with urine samples, Western blotting was the more 
reliable method for the assessment of NY-ESO-1 urine antibody. Nephropathy was excluded as a possible 
reason for increased renal protein loss in all patients. In accordance with previous studies (35), strong NY-ESO-1 
antibody reactivity correlated with NY-ESO-1-specific CD8+ T cell reactivity. All eight HLA-A2+ NY-ESO-1 serum 
and urine antibody-positive patients tested showed a strong NY-ESO-1-specific CD8+ T cell reactivity (data not 
shown). In contrast, none of the patients with weak (3 patients tested) or no NY-ESO-1 serum and urine antibody 
reactivity (5 patients tested) had detectable CD8+ T cell reactivity. There was no correlation between clinical 
features (metastatic sites, treatment) and NY-ESO-1 serum and urine antibody status for the patients with NY-
ESO-1+ malignancies analyzed in this study. However, detectable serum antibody titers were found to correlate 
with the clinical evolution of NY-ESO-1 positive disease in individual patients over time (25). As an easily 
accessible source of material, urine can now be included as a monitoring element in assessing changes in NY-
ESO-1 antibody status.
High-titered antibody responses against several infectious diseases, such as HIV, infection with Helicobacter 
pylori, schistosomiasis, have been found to be associated with detectable levels of urine antibody in patients with 
normal renal function (30, 31, 32, 33). Based on the high concordance of serum and urine antibody 
determinations, urine-based tests are increasingly being considered for antibody screening because they are non-
invasive, painless, and easy to administer. Screening tests have been developed which facilitate the rapid 
detection of urine antibodies with defined specificity for the monitoring of patients at risk for infection.
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Based on the high concordance of NY-ESO-1 serum and urine antibody in strongly seropositive patients, we are 
extending the search for urine antibody reactivity to other defined human cancer antigens that frequently induce 
humoral immune responses (i.e. p53). If urine excretion of antibodies against cancer antigens is not restricted to 
NY-ESO-1, urine-based test systems may be of value for the monitoring or follow-up of spontaneous and vaccine-
induced humoral immune responses against the different cancer antigens expressed by individual tumors. 
Furthermore, the search for new cancer antigens may be improved by screening tumor-derived cDNA expression 
libraries with autologous or allogeneic urine samples, which may represent a source of high-titered antibody 
responses in individual patients. 
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Materials and methods
Patients
All patients in this study were treated in the outpatient department of II. Medizinische Klinik at Krankenhaus 
Nordwest in Frankfurt. Forty-seven patients with advanced NY-ESO-1+ malignancies were selected for the 
assessment of NY-ESO-1 serum and urine antibody. The distribution of patients was as follows: melanoma (12), 
prostate cancer (5), breast cancer (4), stomach cancer (2), non-small cell lung cancer (8), ovarian cancer (4), 
soft tissue sarcoma (4), leiomyosarcoma (1), cholangiocarcinoma (1), non-Hodgkin's lymphoma (1), small cell 
carcinoma (1), multiple myeloma (1), bladder cancer (1), thyroid cancer (1), and neuroendocrine carcinoma (1). 
Multiple serum and urine samples were collected from the patients. Serum and urine samples tested in this 
analysis were taken on the same day or within 4 weeks.
Cell culture
The tumor cell line NW-MEL-38 was cultured in Dulbecco's modified Eagle's medium (DMEM, GIBCO) 
containing 10 mM HEPES buffer, L-arginine (84 mg/l), L-glutamine (584 mg/l), penicillin (10 IU/ml), streptomycin 
(100 µg/ml), and 10% FCS (23).
Eukaryotic expression of NY-ESO-1
The full-length coding sequence of NY-ESO-1 was cloned into the pcDNA3.1(-) expression vector (Invitrogen), 
and this construct was used for the transfection of COS-7 cells as described (23).
Immunoblot Analysis
Serum and urine antibody responses against the recombinant NY-ESO-1 protein were tested by standard 
Western blot analysis (36). Briefly, 1 µg of purified recombinant NY-ESO-1 protein was diluted in SDS and 
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electrophoresed on a 15% SDS polyacrylamide gel. In all assays, the recombinant NY-ESO-1 `short´ protein 
(amino acids 10-121; molecular weight 14 kDa) was used, as we have previously shown that the full length and 
recombinant NY-ESO-1 `short´ proteins are recognized equally well by serum IgG antibodies (26). After 
overnight blotting on a nitrocellulose filter (0.45 µm, Sartorius, Göttingen) and blocking with 3% BSA in TBS, 
blots were incubated with either patients' sera at 1:250, 1:1,000, and 1:10,000 dilution, patients' urine at 1:1, 
1:100, 1:250, and 1:1,000 dilution, or the E978 mouse monoclonal antibody (1:250 dilution) against NY-ESO-1 
as a positive control (26). To show that recognition of the recombinant NY-ESO-1 `short´ protein (14 kDa) by 
serum and urine IgG antibodies corresponds to recognition of the naturally expressed NY-ESO-1 protein (22 
kDa), 5 µl lysate of the NY-ESO-1-expressing melanoma cell line NW-MEL-38 or of COS-7 cells transfected with 
NY-ESO-1 were used. Serum and urine antibodies binding to NY-ESO-1 were detected by incubation with goat 
anti-human IgG (Fc-spec.; Sigma Chemical Co., St. Louis, MO) diluted 1:10,000, or in the case of E978 with goat 
anti-mouse IgG (Bio-Rad, Hercules, CA) diluted 1:3,000, and visualized with NBT/X-phosphate (Sigma). Serum 
and urine samples were considered positive for NY-ESO-1 antibody when reactivity with the 14 kDa recombinant 
NY-ESO-1 `short´ protein and/or the naturally expressed 22 kDa NY-ESO-1 protein was detectable.
ELISA
Recombinant NY-ESO-1 `short´ protein at a concentration of 1 µg/ml in coating buffer (15 mM Na2CO3, 30 mM 
NaHCO3, pH 9.6, with 0.02% NaN3) was adsorbed to TC microwell plates 6 x 10 (Nunc, Roskilde, Denmark) 
overnight at 4°C at 10 µl/well. Plates were washed with PBS and blocked overnight at 4°C with 10 µl/well 2% 
BSA in PBS. After washing, serum and urine dilutions in 2% BSA (10 µl/well) were added and the plates 
incubated for 2 h at room temperature. The plates were then washed, 10 µl/well diluted secondary antibody in 
2% BSA added (goat anti-human IgG-AP; Southern Biotechnology, Birmingham, AL), and the plates incubated 
for 1 h at room temperature. The plates were then washed, incubated with 10 µl/well substrate solution 
(AttoPhos® substrate; JBL Scientific, San Louis Obispo, CA) for 25 min at room temperature and the 
fluorescence immediately determined (Cytofluor 2350; Millipore, Bedford, MA). Four-fold dilutions of sera, 
ranging from 1:100 to 1:100,000, and of urine samples, ranging from 1:1 to 1:250, were tested as described 
previously (26). 
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